What will the average number of measles cases be during Trump's term?
**Assumption:** 'Yes' = the 4-year average annual measles cases in the U.S. during 2025–2028 is >= 1,000. Based on current outbreak size, vaccination trends, and public-health capacity, I assess a **65%** probability that the 4-year average will meet or exceed 1,000 cases/year.
Analysis
**Stage 1 — Blind analysis (ignore market prices):**
The most recent reporting period shows 1,046 measles cases and continuing, expanding outbreaks across multiple states (VA, UT, MD, LA County). Key structural drivers are an ongoing decline in routine MMR coverage in pockets of the U.S., international travel that seeds introductions, and localized communities with low immunity that allow sustained chains of transmission. Historically, once elimination-like status erodes and multiple sizable outbreaks occur in successive years, national case counts can remain elevated for several years: the U.S. 2019 resurgence (1,282 cases) is an example that a single-year large outbreak can presage further risk. The combination of (a) current case counts already at ~1,046 in the latest period, (b) expanding geographic spread, and (c) no strong evidence of a rapid, large-scale reversal in vaccination trends or federal surge funding suggests the baseline risk for 2025–2028 remains elevated.
Balancing that, measles dynamics are responsive to targeted public-health responses: outbreak containment, targeted vaccination campaigns, school entry enforcement, and localized surge funding can sharply reduce transmission. Measles outbreaks are also frequently focal — very high counts in a few jurisdictions can drive national totals upward in a single year. If 2025-2028 includes one very large outbreak year (e.g., >2,000 cases) and other low years, the 4-year average could still exceed 1,000; conversely, if the current rise is primarily a transient cluster and aggressive control measures reduce spread in 2027–2028, the average could fall below 1,000.
Weighing probabilities: given that one year in the current cycle already meets the 1,000 threshold and that vaccination declines and policy constraints on public-health capacity appear to be persistent (per the provided context), it is more likely than not that the 4-year average will be >=1,000. I assign a **65%** independent probability to 'Yes' (average >=1,000/year for 2025–2028). This accounts for the realistic chance of public-health interventions dampening future years (roughly 35% chance), and the possibility some of the years will be much lower or that the current 1,046 is an outlier.
**Stage 2 — Market calibration (compare to the market price):**
Current market: Yes = 0.30, No = 0.70. That price is materially lower than my independent assessment (65%). Possible reasons the market is pricing 'Yes' at ~30%:
- **Ambiguity and misinterpretation risk:** Traders may be uncertain what the exact threshold or averaging method is (calendar year vs. reporting period), or whether the market question was understood as a stricter threshold (e.g., average >1,500) — ambiguity compresses demand for the 'Yes' side. - **Recency illusion and regression-to-the-mean bias:** Many traders may expect that outbreaks burn out quickly and that public-health reaction will drive rapid declines; they overweight the historical long-term low baseline for measles rather than the recent multi-state spread. - **Information asymmetry and conservative traders:** Some sophisticated traders may be waiting for full-year data for 2026–2027 before shifting positions; others may be risk-averse and price in strong policy responses or federal interventions that quickly reduce cases. - **Liquidity and crowd psychology:** With significant event volume (~148k contracts), a coordinated bias or a few large No-side positions can anchor price away from true probability if the market participants are skewed towards pessimism about sustained high measles counts.
Given these explanations, I judge the market is likely underpricing the probability that the 4-year average >=1,000. If the market is genuinely pricing the canonical interpretation (simple arithmetic mean of annual cases 2025–2028 >=1,000), there appears to be a mispricing opportunity: my independent probability of 65% suggests the fair value for 'Yes' should be substantially above 30%. However, this assessment depends on clarity of the question and whether adjustments (e.g., different averaging window, inclusion/exclusion rules) were baked into the contract terms.
Trading implication (if you trade): before acting, verify contract wording and any settlement source definitions. If wording matches the represented threshold, the market price is an attractive buy for 'Yes' vs my 65% belief — but execute only after confirming settlement method and year-by-year counting conventions.
Arguments
For
- Current empirical baseline: the most recent reporting period already shows ~1,046 cases — the 4-year average needs only sustained incidence at roughly that level to meet >=1,000/year.
- Ongoing decline in vaccinations reported by public-health experts reduces herd immunity in pockets and increases probability of repeated, multi-year outbreaks.
- Expanding geographic spread (multiple states) increases the chance outbreaks are not self-limited and will seed further transmission in subsequent years.
- Loss of 'elimination' status implies a structural baseline shift — once elimination is lost, higher multi-year case counts become more likely.
- Policy environment signals (reduced health-research funding, legal challenges, and possible resource constraints) suggest slower or weaker outbreak control capacity.
Against
- Measles is highly visible and politically salient: large outbreaks often trigger swift targeted vaccination campaigns that can sharply reduce transmission within months.
- High national-level vaccine coverage outside clusters still provides substantial protection; outbreaks can remain localized and not sum to high national averages over multiple years.
- Public-health entities are already adapting (e.g., early MMR dosing recommendations for infants), which could meaningfully reduce susceptible pools in coming seasons.
- Past large outbreaks have sometimes been single-year spikes followed by return to low numbers — regression toward the long-term baseline is plausible.
- If the current 1,046 figure represents a partial-year accumulation or an unusually large localized cluster, extrapolating it forward may overstate future annual totals.
Key drivers
- Population-level MMR vaccination coverage and trends in childhood and adolescent immunization
- Geographic clustering of undervaccinated communities and their size (schools, religious/ideological communities)
- International travel importations and global measles incidence
- State and federal public-health response speed and funding (outbreak response teams, catch-up campaigns)
- Local policy levers (school-entry vaccine enforcement, emergency vaccination orders)
- Seasonality and social mixing patterns (school calendars, holiday travel)
Risk factors
- Unclear contract wording or differing definitions for 'average' / data source — settlement ambiguity can invalidate price signals
- Reporting lags and retrospective case adjudication that can materially revise official counts
- Rapid, coordinated vaccination campaigns (state or federal surge funding) that substantially raise coverage in 2026–2028
- Unanticipated shifts in travel patterns or global suppression of measles (fewer importations)
- Behavioral responses by the public (increased vaccine uptake due to outbreak visibility) that reduce future incidence
Scenarios
Best case
For the 'Yes' outcome: Outbreaks continue to expand and at least one or two of the years 2025–2028 have very large nationwide tallies (e.g., >1,500–2,000 cases), while other years remain elevated (500–1,500). That produces a 4-year average comfortably >=1,000. Drivers: sustained vaccine hesitancy, multiple seeding events, and insufficient targeted response capacity.
Most likely
Moderate sustained elevation: 2025–2028 produce a mix of one year at or above ~1,000 (already observed), one moderately high year (600–1,200), and one or two lower years (200–700), yielding a 4-year average around the 800–1,200 range with a tilt toward being >=1,000. This reflects persistent pockets of low coverage combined with intermittent effective outbreak responses.
Worst case
For the 'No' outcome (average <1,000): The current rise is mostly localized and is aggressively suppressed by rapid, well-funded state and federal responses; catch-up campaigns and school enforcement raise coverage; travel patterns change and importations drop — resulting in at least two low years bringing the 4-year average below 1,000.
More from this day
- politicsPolymarketEnded
US forces enter Venezuela again by...?
AI12%MKT97%Edge-85HypedI assess a low probability (12%) that active US military personnel will physically enter Venezuelan land territory by June 30, 2026; the very short remaining window and high political/operational barriers make such an operation unlikely absent an urgent, unforeseen trigger.
- sportsPolymarketEnded
World Cup: Team to advance to Knockout Stages
AI62%MKT19%Edge+43Hidden GemI assess a moderately better-than-market chance that South Korea advances to the Round of 32, reflecting their historical strength and the favorable 2-of-3 group structure but tempered by uncertainty about their specific group draw, recent form, and match circumstances.
- PoliticsKalshi2y
Who will Trump pardon?
AI3%MKT46%Edge-43HypedExtremely unlikely — I assess a low single-digit chance (~3%) that Barron Trump will receive a presidential pardon before Jan 21, 2029; pardons are legally possible absent conviction, but there is no factual or political path that makes this plausible at scale.